Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 640,347 shares, a growth of 500.4% from the March 15th total of 106,655 shares. Based on an average daily volume of 832,163 shares, the days-to-cover ratio is presently 0.8 days. Currently, 6.5% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on APRE shares. HC Wainwright cut their price objective on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a report on Tuesday, March 31st. Wedbush reissued an “outperform” rating and issued a $7.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, March 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Finally, Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aprea Therapeutics currently has a consensus rating of “Hold” and an average price target of $4.10.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.67% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Stock Performance

Shares of NASDAQ APRE traded up $0.18 during mid-day trading on Friday, hitting $0.92. The stock had a trading volume of 1,473,975 shares, compared to its average volume of 2,113,347. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.22. The business has a 50 day moving average price of $0.74 and a two-hundred day moving average price of $1.02. The firm has a market cap of $10.50 million, a P/E ratio of -0.46 and a beta of 1.47.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Monday, March 16th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.06. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 96.33%. The company had revenue of $0.00 million for the quarter. Equities research analysts predict that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.